.

Pharmaceutical Business Intelligence

  • Find generic sources and suppliers
  • Predict branded drug patent expiration
  • Identify first generic entrants

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

CARDIZEM LA Drug Profile

« Back to Dashboard

Which patents cover Cardizem La, and what substitute generic drugs are available?

Cardizem La is a drug marketed by Valeant Intl and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has twenty patent family members in eleven countries.

The generic ingredient in CARDIZEM LA is diltiazem hydrochloride. There are twenty-six drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the diltiazem hydrochloride profile page.

Summary for Tradename: CARDIZEM LA

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list82
Clinical Trials: see list3
Patent Applications: see list11,347
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:CARDIZEM LA at DailyMed

Pharmacology for Tradename: CARDIZEM LA

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Intl
CARDIZEM LA
diltiazem hydrochloride
TABLET, EXTENDED RELEASE;ORAL021392-001Feb 6, 2003RXYesNo7,108,866► SubscribeY ► Subscribe
Valeant Intl
CARDIZEM LA
diltiazem hydrochloride
TABLET, EXTENDED RELEASE;ORAL021392-004Feb 6, 2003RXYesNo7,108,866► SubscribeY ► Subscribe
Valeant Intl
CARDIZEM LA
diltiazem hydrochloride
TABLET, EXTENDED RELEASE;ORAL021392-002Feb 6, 2003RXYesNo6,923,984► SubscribeY ► Subscribe
Valeant Intl
CARDIZEM LA
diltiazem hydrochloride
TABLET, EXTENDED RELEASE;ORAL021392-006Feb 6, 2003RXYesYes6,923,984► SubscribeY ► Subscribe
Valeant Intl
CARDIZEM LA
diltiazem hydrochloride
TABLET, EXTENDED RELEASE;ORAL021392-004Feb 6, 2003RXYesNo6,923,984► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: CARDIZEM LA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Intl
CARDIZEM LA
diltiazem hydrochloride
TABLET, EXTENDED RELEASE;ORAL021392-001Feb 6, 20035,288,505► Subscribe
Valeant Intl
CARDIZEM LA
diltiazem hydrochloride
TABLET, EXTENDED RELEASE;ORAL021392-003Feb 6, 20035,529,791► Subscribe
Valeant Intl
CARDIZEM LA
diltiazem hydrochloride
TABLET, EXTENDED RELEASE;ORAL021392-004Feb 6, 20035,288,505► Subscribe
Valeant Intl
CARDIZEM LA
diltiazem hydrochloride
TABLET, EXTENDED RELEASE;ORAL021392-006Feb 6, 20035,288,505► Subscribe
Valeant Intl
CARDIZEM LA
diltiazem hydrochloride
TABLET, EXTENDED RELEASE;ORAL021392-005Feb 6, 20035,288,505► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CARDIZEM LA

Drugname Dosage Strength RLD Submissiondate
diltiazem hydrochlorideExtended-release Tablets120 mg, 180 mg, 240 mg, 300 mg and 360 mgCardizem LA8/30/2005
diltiazem hydrochlorideExtended-release Tablets420 mgCardizem LA4/25/2005

International Patent Family for Tradename: CARDIZEM LA

Country Document Number Estimated Expiration
Austria430561► Subscribe
World Intellectual Property Organization (WIPO)0141744► Subscribe
Canada2566590► Subscribe
European Patent Office1235562► Subscribe
European Patent Office1131057► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc